Mitsubishi Tanabe Pharma America, Inc.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2015-01-01
- Employees
- 101
- Market Cap
- -
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Esophageal CancerGastric CancerBiliary Tract CancerPancreatic Ductal Adenocarcinoma (PDAC)Breast CancerOvarian CancerCervical CancerEndometrial Cancer
- Interventions
- First Posted Date
- 2025-04-24
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Mitsubishi Tanabe Pharma America Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT06943521
- Locations
- 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP
- Conditions
- Erythropoietic Protoporphyria (EPP)X-Linked Protoporphyria (XLP)
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Mitsubishi Tanabe Pharma America Inc.
- Target Recruit Count
- 165
- Registration Number
- NCT06144840
- Locations
- 🇺🇸
Marvel Clinical Research, LLC, Huntington Beach, California, United States
🇺🇸University of California at San Francisco, San Francisco, California, United States
🇳🇱Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands
Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects
- First Posted Date
- 2022-02-15
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- Mitsubishi Tanabe Pharma America Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT05241535
- Locations
- 🇺🇸
Daytona Beach Clinical Research Unit, Daytona Beach, Florida, United States
🇺🇸Dallas Clinical Research Unit, Dallas, Texas, United States
Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Mitsubishi Tanabe Pharma America Inc.
- Target Recruit Count
- 202
- Registration Number
- NCT05151471
- Locations
- 🇺🇸
Nerve And Muscle Center Of Texas, Houston, Texas, United States
🇺🇸University of Washington Medical Center, Seattle, Washington, United States
🇺🇸University Of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
- First Posted Date
- 2021-08-16
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Mitsubishi Tanabe Pharma America Inc.
- Target Recruit Count
- 301
- Registration Number
- NCT05005975
- Locations
- 🇺🇸
University of California at San Francisco - CSF Porphyria Center, San Francisco, California, United States
🇺🇸University Of Miami School Of Medicine, Center For Liver Diseases, Miami, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Study to Investigate Drug-Drug Interaction Between MT-7117 and Test Drugs in Healthy Subjects
- First Posted Date
- 2021-03-11
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- Mitsubishi Tanabe Pharma America Inc.
- Target Recruit Count
- 112
- Registration Number
- NCT04793295
- Locations
- 🇺🇸
Advanced Pharma CR, LLC, Miami, Florida, United States
🇺🇸Worldwide Clinical Trials, San Antonio, Texas, United States
Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Mitsubishi Tanabe Pharma America Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT04683848
- Locations
- 🇺🇸
University of California Irvine, Orange, California, United States
🇺🇸Tallahassee Neurological Clinic, Tallahassee, Florida, United States
🇺🇸Augusta University, Augusta, Georgia, United States
PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal Function
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2023-05-15
- Lead Sponsor
- Mitsubishi Tanabe Pharma America Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT04656795
- Locations
- 🇩🇪
Clinical Research Services (CRS) Kiel GmbH, Kiel, Germany
Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)
- First Posted Date
- 2020-10-06
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Mitsubishi Tanabe Pharma America Inc.
- Target Recruit Count
- 124
- Registration Number
- NCT04577404
- Locations
- 🇯🇵
National Hospital Organization Kumamoto Saishun Medical Center, Koshi-shi, Kumamoto, Japan
🇯🇵Kansai Electric Power Hospital Recruiting, Fukushima-ku, Osaka-shi, Osaka, Japan
🇯🇵Tokyo Metropolitan Neurological Hospital, Fuchu-city, Tokyo, Japan
Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS
- First Posted Date
- 2020-09-29
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Mitsubishi Tanabe Pharma America Inc.
- Target Recruit Count
- 384
- Registration Number
- NCT04569084
- Locations
- 🇺🇸
Thomas Jefferson University, Jefferson Weinberg ALS Center, Philadelphia, Pennsylvania, United States
🇺🇸UF Health Cancer Center, Gainesville, Florida, United States
🇺🇸University California Los Angeles Medical Center (UCLA), Los Angeles, California, United States